![Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial - The Lancet Rheumatology Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/dad580fb-1278-4fc7-ae5b-1f405d46bc90/gr1.gif)
Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial - The Lancet Rheumatology
![Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches - The Lancet Neurology Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches - The Lancet Neurology](https://www.thelancet.com/cms/attachment/bd645874-312e-4be0-b348-c647904c99b2/gr1.jpg)
Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches - The Lancet Neurology
Center for Complex Neurology, EDS & POTS - Some disorders of muscle can be caused by inflammation from a person's own immune system. This is called an Autoimmune Myopathy or Myositis. Polymyositis
![Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis - Lindgren - 2022 - Annals of Neurology - Wiley Online Library Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis - Lindgren - 2022 - Annals of Neurology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ab1f90a2-315f-43f1-bcd5-c980a8f800eb/ana26412-fig-0001-m.jpg)
Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis - Lindgren - 2022 - Annals of Neurology - Wiley Online Library
![Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial - The Lancet Neurology Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/e42bfe7e-16bb-42be-9202-b81aa80fe74c/gr1.jpg)